glp-1 for alcohol use disorder

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial — Phot

Ending Obesity Treatment Lies, Revealing Truth

GLP-1 receptor agonists can simultaneously treat obesity and alcohol use disorder, and a 12-week Lancet trial showed weekly semaglutide injections cut heavy drinking days by 39% versus placebo. In my practice, the idea of a single pill tackling two of the most stubborn health challenges feels like a breakthrough worth